In its second major partnership with a big pharma group, UK-based AI and multi-omics company Relation Therapeutics has agreed to seek out targets for allergic diseases on behalf of Novartis. The ...

Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...

Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...

A common over-the-counter medication could significantly reduce the risk of colorectal cancer coming back. In a Swedish study, a low dose of aspirin was shown to slash recurrence in half for patients ...

One large study found that more advanced cases of colorectal cancer had a higher likelihood of returning. For example, if participants had stage 3 colon cancer, almost 25 percent experienced a ...

CHICAGO--(BUSINESS WIRE)--Relation Insurance Services (“Relation”) acquired the assets of Advantage Insurance Group. The transaction went into effect on May 31, 2025; terms of the transaction were not ...

Justin Stebbing does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Exercise is generally good for you, but a new high-quality clinical trial finds that it’s so good, it can even knock back colon cancer—and, in fact, rival some chemotherapy treatments. The finding ...

Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...

It’s common for patients to fear that their cancer will return. Breast cancer is the most prevalent form of cancer, so it makes sense that fear of recurrence among its survivors is especially ...